IoGen: Phase II

SYMBA reported additional data from its 111-patient Phase II trial (see BioCentury, Aug. 21). In the 6 mg

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE